Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases.
A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement.
This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.
"synopsis" may belong to another edition of this title.
Professor Emeritus of Immunology and Pathology
School of Medicine and Surgery
Coordinator of the Teachers’ Committee for the Master in Translational Biomedicine
Universita degli Studi di Verona, Italy
"About this title" may belong to another edition of this title.
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand. Seller Inventory # 41ba3a6b67503e08dc3d7a539dffc21e
Quantity: Over 20 available
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. 715 pages. 10.50x8.25x2.00 inches. In Stock. Seller Inventory # zk0128094001
Quantity: 1 available